Phaseline

Companies › Shandong Boan Biotechnology

Shandong Boan Biotechnology: clinical trials, targets and expected readouts

6 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LY01015
PD-1 inhibitor
–Phase 3Esophageal Squamous Cell Carcinoma–
BA1202–Phase 1Advanced Solid TumorDec 2026
BA1301–Phase 1Advanced Solid TumoursJun 2027
BA1106–Phase 1Solid TumorsDec 2027
BA1302–Phase 1Non-Small Cell Lung CancerDec 2027
BA1203–Phase 1Solid TumorsDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06022861LY01015Phase 3Esophageal Squamous Cell CarcinomaOncologyMay 2026
NCT05909241BA1202Phase 1Advanced Solid TumorOncologyDec 2026
NCT06927349BA1301Phase 1Advanced Solid TumoursOncologyJun 2027
NCT05650242BA1106Phase 1Solid TumorsOncologyDec 2027
NCT06596915BA1302Phase 1Non-Small Cell Lung CancerOncologyDec 2027
NCT07876609BA1203Phase 1Solid TumorsOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

TORL Biotherapeutics Nanjing Sanhome Pharmaceutical Taiho Pharmaceutical Minghui Pharmaceutical (Hangzhou) Day One Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.